Mutations increasing MEK1 activation and bolstering resistance to MEK inhibitors have been shown to develop in colon cancer cell lines and even in a patient with resistant melanoma that developed after MEK inhibitor use [303]. Here, MAP2K7 is linked to malignant colon neoplasm.